RU2016131167A - Способы лечения, диагностики и мониторинга волчанки - Google Patents
Способы лечения, диагностики и мониторинга волчанки Download PDFInfo
- Publication number
- RU2016131167A RU2016131167A RU2016131167A RU2016131167A RU2016131167A RU 2016131167 A RU2016131167 A RU 2016131167A RU 2016131167 A RU2016131167 A RU 2016131167A RU 2016131167 A RU2016131167 A RU 2016131167A RU 2016131167 A RU2016131167 A RU 2016131167A
- Authority
- RU
- Russia
- Prior art keywords
- locus
- variation
- subject
- snp
- lupus
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 103
- 206010025135 lupus erythematosus Diseases 0.000 title claims 45
- 238000012544 monitoring process Methods 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims 55
- 125000003729 nucleotide group Chemical group 0.000 claims 55
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 claims 14
- 108700028369 Alleles Proteins 0.000 claims 12
- 230000007614 genetic variation Effects 0.000 claims 12
- 229940113082 thymine Drugs 0.000 claims 9
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000002068 genetic effect Effects 0.000 claims 8
- 102100034622 Complement factor B Human genes 0.000 claims 7
- 101000710032 Homo sapiens Complement factor B Proteins 0.000 claims 7
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 claims 7
- 101001056560 Homo sapiens Juxtaposed with another zinc finger protein 1 Proteins 0.000 claims 7
- 101000946275 Homo sapiens Protein CLEC16A Proteins 0.000 claims 7
- 101000616523 Homo sapiens SH2B adapter protein 3 Proteins 0.000 claims 7
- 101000663000 Homo sapiens TNFAIP3-interacting protein 1 Proteins 0.000 claims 7
- 101000807276 Homo sapiens UHRF1-binding protein 1 Proteins 0.000 claims 7
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 claims 7
- 102000006445 IFIH1 Interferon-Induced Helicase Human genes 0.000 claims 7
- 108090000174 Interleukin-10 Proteins 0.000 claims 7
- 102000003814 Interleukin-10 Human genes 0.000 claims 7
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 claims 7
- 102100025727 Juxtaposed with another zinc finger protein 1 Human genes 0.000 claims 7
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims 7
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 7
- 102100034718 Protein CLEC16A Human genes 0.000 claims 7
- 102100021778 SH2B adapter protein 3 Human genes 0.000 claims 7
- 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 claims 7
- 102100037610 UHRF1-binding protein 1 Human genes 0.000 claims 7
- 238000003745 diagnosis Methods 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 7
- 210000003917 human chromosome Anatomy 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 4
- 238000010348 incorporation Methods 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27851009P | 2009-10-07 | 2009-10-07 | |
| US61/278,510 | 2009-10-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012118596/10A Division RU2596391C2 (ru) | 2009-10-07 | 2010-10-06 | Способ диагностики волчанки у человека |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016131167A true RU2016131167A (ru) | 2018-12-07 |
Family
ID=43857111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012118596/10A RU2596391C2 (ru) | 2009-10-07 | 2010-10-06 | Способ диагностики волчанки у человека |
| RU2016131167A RU2016131167A (ru) | 2009-10-07 | 2010-10-06 | Способы лечения, диагностики и мониторинга волчанки |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012118596/10A RU2596391C2 (ru) | 2009-10-07 | 2010-10-06 | Способ диагностики волчанки у человека |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20130034544A1 (enExample) |
| EP (3) | EP3219813B1 (enExample) |
| JP (2) | JP5937008B2 (enExample) |
| KR (2) | KR101953075B1 (enExample) |
| CN (2) | CN106929568A (enExample) |
| BR (1) | BR112012007778A2 (enExample) |
| CA (1) | CA2777055C (enExample) |
| RU (2) | RU2596391C2 (enExample) |
| WO (1) | WO2011044205A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3219813B1 (en) | 2009-10-07 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Methods for diagnosing lupus |
| US20130310266A1 (en) * | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| KR20140034529A (ko) | 2012-09-12 | 2014-03-20 | 삼성전기주식회사 | 전기 동도금 장치 |
| WO2014058254A1 (ko) * | 2012-10-10 | 2014-04-17 | 가톨릭대학교 산학협력단 | １ｑ２５．１(RABGAP1L) 위치, 6P21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물 |
| KR101491214B1 (ko) * | 2012-10-10 | 2015-02-06 | 가톨릭대학교 산학협력단 | １ｑ２５．１(RABGAP1L) 위치, 6p21.32 (C4) 위치 및 １０ｑ２１．３위치의 ＤＮＡ 복제 수 변이 검출용 프라이머를 포함하는 전신성 홍반성 루푸스 발병 위험도 예측용 조성물 |
| US20170081723A1 (en) * | 2014-03-21 | 2017-03-23 | Agency For Science, Technology And Research | Fusion Genes in Cancer |
| DE102017107661A1 (de) | 2017-04-10 | 2018-10-11 | Universität Rostock | SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort |
| KR20190034511A (ko) | 2019-03-22 | 2019-04-02 | 아주대학교산학협력단 | Aimp1을 포함하는 전신 홍반성 루프스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루프스 진단 방법 |
| EP4076671A4 (en) * | 2019-12-18 | 2024-04-17 | The Children's Hospital Of Philadelphia | Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same |
| KR20240019341A (ko) * | 2021-07-15 | 2024-02-14 | 후지필름 가부시키가이샤 | 세포의 품질 관리 방법 및 세포를 제조하는 방법 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0912761A4 (en) | 1996-05-29 | 2004-06-09 | Cornell Res Foundation Inc | DETERMINATION OF DIFFERENCES IN THE NUCLEIC ACID SEQUENCE BY MEANS OF A COMBINATION OF LIGASE DETERMINATION AND POLYMERASE CHAIN REACTION |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU6534600A (en) * | 1999-08-09 | 2001-03-05 | Uab Research Foundation | Genetic polymorphism in the il-10 promoter |
| AU2001265121A1 (en) | 2000-05-30 | 2001-12-11 | Applera Corporation | Methods for detecting target nucleic acids using coupled ligation and amplification |
| WO2002018414A2 (en) * | 2000-08-29 | 2002-03-07 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the bf gene |
| US6900016B1 (en) | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
| NZ525336A (en) | 2000-10-20 | 2006-03-31 | Expression Diagnostics Inc | Leukocyte expression profiling |
| US7205106B1 (en) | 2001-07-20 | 2007-04-17 | Roche Molecular Systems, Inc. | Association of polymorphisms in IL4-related genes with autoimmune disease |
| JP2003061677A (ja) | 2001-08-28 | 2003-03-04 | Olympus Optical Co Ltd | 全身性エリテマトーデスの感受性遺伝子およびその使用 |
| US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
| US7022476B2 (en) | 2002-02-26 | 2006-04-04 | New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery | Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof |
| US7584058B2 (en) * | 2003-02-27 | 2009-09-01 | Methexis Genomics N.V. | Genetic diagnosis using multiple sequence variant analysis |
| EP1608783A2 (en) | 2003-03-18 | 2005-12-28 | Applera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| WO2005086872A2 (en) | 2004-03-10 | 2005-09-22 | Celera, An Applera Corporation Business | Ptpn22 polymorphisms in diagnosis and therapy |
| DE102005003686A1 (de) | 2005-01-26 | 2006-08-03 | Rohde & Schwarz Gmbh & Co. Kg | Anordnung zum Glätten des einem Verbraucher zugeführten Verbraucherstromes |
| AU2006272597A1 (en) * | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
| EP2327792B9 (en) | 2005-08-05 | 2013-12-18 | Genentech, Inc. | Methods and compositions for detecting auto-immune disorders |
| US20070231816A1 (en) * | 2005-12-09 | 2007-10-04 | Baylor Research Institute | Module-Level Analysis of Peripheral Blood Leukocyte Transcriptional Profiles |
| US20070238094A1 (en) * | 2005-12-09 | 2007-10-11 | Baylor Research Institute | Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis |
| BRPI0708902A2 (pt) | 2006-03-16 | 2011-06-14 | Genentech Inc | mÉtodos de tratar lupus usando anticorpos cd4 |
| CN101443040A (zh) * | 2006-03-16 | 2009-05-27 | 基因技术股份有限公司 | 用cd4抗体治疗狼疮的方法 |
| US20070269827A1 (en) | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
| EP2639318B1 (en) * | 2006-09-11 | 2015-04-08 | Celera Corporation | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof |
| US20100322928A1 (en) * | 2007-01-19 | 2010-12-23 | Yeda Research And Development Co., Ltd. | Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle) |
| US7695916B2 (en) * | 2007-03-22 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof |
| CN103298950B (zh) * | 2007-05-21 | 2015-01-21 | 健泰科生物技术公司 | 用于鉴定和治疗狼疮的方法和组合物 |
| WO2009015087A2 (en) * | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
| US8008013B2 (en) * | 2007-11-16 | 2011-08-30 | Oklahoma Medical Research Foundation | Predicting and diagnosing patients with autoimmune disease |
| US20090307180A1 (en) * | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| DE102008031958A1 (de) | 2008-07-07 | 2010-01-14 | Klebchemie M.G. Becker Gmbh & Co. Kg | Verfahren zum Laminieren von Hochglanzoberflächen |
| MX2011003273A (es) * | 2008-09-26 | 2011-04-28 | Genentech Inc | Metodo para tratar, diagnosticar y supervisar lupus. |
| EP3219813B1 (en) | 2009-10-07 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Methods for diagnosing lupus |
-
2010
- 2010-10-06 EP EP17158497.2A patent/EP3219813B1/en active Active
- 2010-10-06 WO PCT/US2010/051589 patent/WO2011044205A1/en not_active Ceased
- 2010-10-06 CN CN201611005880.7A patent/CN106929568A/zh active Pending
- 2010-10-06 CA CA2777055A patent/CA2777055C/en active Active
- 2010-10-06 KR KR1020187002464A patent/KR101953075B1/ko not_active Expired - Fee Related
- 2010-10-06 US US13/501,448 patent/US20130034544A1/en not_active Abandoned
- 2010-10-06 CN CN202110273784.5A patent/CN113025703A/zh active Pending
- 2010-10-06 RU RU2012118596/10A patent/RU2596391C2/ru active
- 2010-10-06 JP JP2012533270A patent/JP5937008B2/ja not_active Expired - Fee Related
- 2010-10-06 BR BR112012007778-3A patent/BR112012007778A2/pt not_active Application Discontinuation
- 2010-10-06 KR KR1020127011605A patent/KR101824744B1/ko not_active Expired - Fee Related
- 2010-10-06 EP EP20198258.4A patent/EP3839068A3/en not_active Withdrawn
- 2010-10-06 RU RU2016131167A patent/RU2016131167A/ru not_active Application Discontinuation
- 2010-10-06 EP EP10822583.0A patent/EP2486152B1/en active Active
-
2016
- 2016-02-10 US US15/040,949 patent/US10053734B2/en active Active
- 2016-05-11 JP JP2016095330A patent/JP6321717B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-20 US US16/105,426 patent/US20190211398A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2596391C2 (ru) | 2016-09-10 |
| EP2486152A1 (en) | 2012-08-15 |
| EP3839068A3 (en) | 2021-10-20 |
| JP6321717B2 (ja) | 2018-05-09 |
| CN102803509A (zh) | 2012-11-28 |
| CA2777055C (en) | 2021-04-06 |
| JP2017012158A (ja) | 2017-01-19 |
| BR112012007778A2 (pt) | 2020-08-11 |
| RU2012118596A (ru) | 2013-11-20 |
| US20130034544A1 (en) | 2013-02-07 |
| CA2777055A1 (en) | 2011-04-14 |
| JP2013507127A (ja) | 2013-03-04 |
| CN113025703A (zh) | 2021-06-25 |
| US20190211398A1 (en) | 2019-07-11 |
| US10053734B2 (en) | 2018-08-21 |
| US20160273044A1 (en) | 2016-09-22 |
| JP5937008B2 (ja) | 2016-06-22 |
| EP3219813A2 (en) | 2017-09-20 |
| CN106929568A (zh) | 2017-07-07 |
| EP3219813B1 (en) | 2020-11-18 |
| EP3219813A3 (en) | 2018-01-10 |
| KR20120100969A (ko) | 2012-09-12 |
| KR101824744B1 (ko) | 2018-03-15 |
| EP3839068A2 (en) | 2021-06-23 |
| HK1176384A1 (zh) | 2013-07-26 |
| EP2486152B1 (en) | 2017-12-06 |
| KR101953075B1 (ko) | 2019-02-27 |
| EP2486152A4 (en) | 2013-05-22 |
| KR20180012344A (ko) | 2018-02-05 |
| WO2011044205A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016131167A (ru) | Способы лечения, диагностики и мониторинга волчанки | |
| JP2010507388A5 (enExample) | ||
| JP2012503985A5 (enExample) | ||
| JP2008526249A5 (enExample) | ||
| JP2013507127A5 (enExample) | ||
| WO2013170215A1 (en) | Methods for predicting and detecting cancer risk | |
| RU2009147281A (ru) | Способы и композиции для диагностики и лечения волчанки | |
| JP2010528590A5 (enExample) | ||
| WO2003089897A3 (en) | Diagnosis and treatment of vascular disease | |
| US20210180129A1 (en) | Methods of predicting the development of amd based on chromosome 1 and chromosome10 | |
| JP2011530312A5 (enExample) | ||
| JP2010510804A5 (enExample) | ||
| WO2012171990A1 (en) | Discrimination of blood type variants | |
| JP5226256B2 (ja) | 加齢黄斑変性症の発症リスクの予測方法 | |
| JP2018516231A (ja) | Ｃｒｈｒ１拮抗薬を用いた治療に対する反応の遺伝子予測因子を用いた治療の方法 | |
| KR20130041767A (ko) | 정상 안압 녹내장 질환 감수성 유전자 및 그 이용 | |
| WO2003026488A3 (en) | Diagnosis and treatment of vascular disease | |
| JP2013126422A (ja) | 加齢黄斑変性症の発症リスクの予測方法 | |
| KR102158673B1 (ko) | 양극성장애 환자의 계절성 또는 일주기 변화 진단을 위한 단일염기다형성 마커를 이용한 정보 제공 방법 | |
| JP6053681B2 (ja) | イヌの緑内障を診断する方法及びキット | |
| EP3315613B1 (en) | Methods and kits for diagnosing or assessing the risk of cervical cancer | |
| JP5866669B2 (ja) | 乳がん発症感受性の判定方法 | |
| Webb et al. | Model-based gene selection shows engrailed 1 is associated with antipsychotic response | |
| CN105765077B (zh) | 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒 | |
| WO2016180725A1 (en) | Diagnosis of dementia with lewy bodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190729 |